Pfizer issues 2025 outlook, reiterates 2024 guidance

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant issued its full-year 2025 guidance and reaffirmed its full-year 2024 outlook in line with Street forecasts.

The company expects its full-year 2025 revenues and adjusted diluted earnings per share to reach $61.0B-$64.0B and $2.80-$3.00, respectively, compared to $63.28B and $2.88 in the consensus.

Its unchanged 2024 outlook for revenue and adjusted diluted EPS stand at $61.0B–$64.0B and $2.75–$2.95 compared to $62.88B and $2.93 projected by analysts, respectively.

Its 2025 outlook includes about $1B net unfavorable impact related to the Medicare Part D Redesign changes, specifically the $2,000 annual out-of-pocket cap required from the 2022 Inflation Reduction Act (IRA).

The COVID-19 vaccine maker said it has realized $4B in net cost savings through 2024 and intends to achieve $500M in additional savings next year through the ongoing cost realignment program.

Pfizer (NYSE:PFE) will hold an analyst webcast on Tuesday at 8:30 a.m. EST to provide additional commentary.